RU2706787C2 - Модель сухого кератоконъюнктивита на животных и способы применения таких животных - Google Patents

Модель сухого кератоконъюнктивита на животных и способы применения таких животных Download PDF

Info

Publication number
RU2706787C2
RU2706787C2 RU2017118978A RU2017118978A RU2706787C2 RU 2706787 C2 RU2706787 C2 RU 2706787C2 RU 2017118978 A RU2017118978 A RU 2017118978A RU 2017118978 A RU2017118978 A RU 2017118978A RU 2706787 C2 RU2706787 C2 RU 2706787C2
Authority
RU
Russia
Prior art keywords
scopolamine
eye
candidate agent
benzalkonium chloride
administered
Prior art date
Application number
RU2017118978A
Other languages
English (en)
Russian (ru)
Other versions
RU2017118978A (ru
RU2017118978A3 (enExample
Inventor
Мин ЮАНЬ
Ин ХУ
Цзинтай ЦАО
Кармело РОМАНО
Original Assignee
Регенерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Регенерон Фармасьютикалз, Инк. filed Critical Регенерон Фармасьютикалз, Инк.
Publication of RU2017118978A publication Critical patent/RU2017118978A/ru
Publication of RU2017118978A3 publication Critical patent/RU2017118978A3/ru
Application granted granted Critical
Publication of RU2706787C2 publication Critical patent/RU2706787C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B23/00—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
    • G09B23/28—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for medicine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Educational Technology (AREA)
  • Pure & Applied Mathematics (AREA)
  • Medical Informatics (AREA)
  • Mathematical Analysis (AREA)
  • Mathematical Optimization (AREA)
  • Theoretical Computer Science (AREA)
  • Algebra (AREA)
  • Business, Economics & Management (AREA)
RU2017118978A 2014-12-02 2015-12-01 Модель сухого кератоконъюнктивита на животных и способы применения таких животных RU2706787C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086263P 2014-12-02 2014-12-02
US62/086,263 2014-12-02
PCT/US2015/063084 WO2016089807A1 (en) 2014-12-02 2015-12-01 Animal model for dry eye and methods of use of such animals

Publications (3)

Publication Number Publication Date
RU2017118978A RU2017118978A (ru) 2019-01-09
RU2017118978A3 RU2017118978A3 (enExample) 2019-06-04
RU2706787C2 true RU2706787C2 (ru) 2019-11-21

Family

ID=55024246

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017118978A RU2706787C2 (ru) 2014-12-02 2015-12-01 Модель сухого кератоконъюнктивита на животных и способы применения таких животных

Country Status (14)

Country Link
US (1) US20170360013A1 (enExample)
EP (1) EP3226853B1 (enExample)
JP (1) JP6692808B2 (enExample)
KR (1) KR20170100483A (enExample)
CN (1) CN107106553A (enExample)
AU (1) AU2015355169A1 (enExample)
CA (1) CA2967432A1 (enExample)
ES (1) ES2759729T3 (enExample)
IL (1) IL252077A0 (enExample)
MX (1) MX2017007295A (enExample)
RU (1) RU2706787C2 (enExample)
SG (1) SG11201703572SA (enExample)
WO (1) WO2016089807A1 (enExample)
ZA (1) ZA201703052B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2909998T3 (es) * 2016-10-14 2022-05-11 I Com Medical Gmbh Método para establecer, restablecer y preservar la homeostasis de la superficie ocular
US12303527B2 (en) 2018-04-18 2025-05-20 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
US12268706B2 (en) 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
KR102429281B1 (ko) * 2020-05-25 2022-08-05 (주)노바셀테크놀로지 신규 안구건조증 치료용 약학적 조성물
CN113519461A (zh) * 2021-07-06 2021-10-22 江西中洪博元生物技术有限公司 伴刀豆球蛋白a诱导的小鼠干眼症模型的构建方法及应用
WO2023215261A1 (en) * 2022-05-02 2023-11-09 Ocular Services On Demand, Llc Mammalian eye models

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012013884A1 (fr) * 2010-07-29 2012-02-02 Laboratoires Fournier Sa Composes pour le traitement/la prevention des maladies inflammatoires oculaires

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2384679A1 (en) * 1999-09-08 2001-03-15 Srinivasan Venkateshwaran Using quaternary ammonium salts for transdermal drug delivery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012013884A1 (fr) * 2010-07-29 2012-02-02 Laboratoires Fournier Sa Composes pour le traitement/la prevention des maladies inflammatoires oculaires

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEYAZYILDIZ Е. et al. Efficacy of Topical Mesenchymal Stem Cell Therapy in the Treatment of Experimental Dry Eye Syndrome *
LI R. et al. An NGF Mimetic, MIM-D3, Demonstrates Therapeutic Efficacy in a Rat Model of Scopoloamine-Induced Dry Eye//ARVO Annual Meeting Abstract, April 2009, Volume 50, Issue 13, 3661, . *
LI R. et al. An NGF Mimetic, MIM-D3, Demonstrates Therapeutic Efficacy in a Rat Model of Scopoloamine-Induced Dry Eye//ARVO Annual Meeting Abstract, April 2009, Volume 50, Issue 13, 3661, реферат. BEYAZYILDIZ Е. et al. Efficacy of Topical Mesenchymal Stem Cell Therapy in the Treatment of Experimental Dry Eye Syndrome Model//Stem Cells Int. 2014; 2014: 250230.Published online 2014 Jul 17. doi: 10.1155/2014/250230. *

Also Published As

Publication number Publication date
RU2017118978A (ru) 2019-01-09
ES2759729T3 (es) 2020-05-12
EP3226853A1 (en) 2017-10-11
CN107106553A (zh) 2017-08-29
KR20170100483A (ko) 2017-09-04
SG11201703572SA (en) 2017-05-30
CA2967432A1 (en) 2016-06-09
US20170360013A1 (en) 2017-12-21
IL252077A0 (en) 2017-07-31
RU2017118978A3 (enExample) 2019-06-04
MX2017007295A (es) 2018-03-12
JP6692808B2 (ja) 2020-05-13
EP3226853B1 (en) 2019-09-04
AU2015355169A1 (en) 2017-05-25
WO2016089807A1 (en) 2016-06-09
ZA201703052B (en) 2019-03-27
JP2018500546A (ja) 2018-01-11

Similar Documents

Publication Publication Date Title
Yu et al. Neurokinin-1 receptor antagonism ameliorates dry eye disease by inhibiting antigen-presenting cell maturation and T helper 17 cell activation
De Paiva et al. Dry eye–induced conjunctival epithelial squamous metaplasia is modulated by interferon-γ
EP3226853B1 (en) Animal model for dry eye and methods of use of such animals
Solomon et al. Pro-and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease
Ebihara et al. Role of the IL-6 classic-and trans-signaling pathways in corneal sterile inflammation and wound healing
Keane–Myers et al. Prevention of allergic eye disease by treatment with IL-1 receptor antagonist
Reins et al. MyD88 deficiency protects against dry eye–induced damage
Ciprandi et al. Terfenadine exerts antiallergic activity reducing ICAM‐1 expression on nasal epithelial cells in patients with pollen allergy
Goldberg et al. G-CSF and neutrophils are nonredundant mediators of murine experimental autoimmune uveoretinitis
Dietrich et al. Comparative analysis on the dynamic of lacrimal gland damage and regeneration after Interleukin-1α or duct ligation induced dry eye disease in mice
Vitar et al. Topical neurokinin-1 receptor antagonist Fosaprepitant ameliorates ocular graft-versus-host disease in a preclinical mouse model
CN114555107A (zh) 用于干眼病的tsg6多肽片段
Jin et al. Anti-inflammatory effects of glycine thymosin β4 eye drops in experimental dry eye
Turner et al. STAT6-mediated keratitis and blepharitis: a novel murine model of ocular atopic dermatitis
Hosotani et al. IL-33-induced keratoconjunctivitis is mediated by group 2 innate lymphoid cells in mice
Okada et al. TNFalpha suppression of corneal epithelium migration
Tan et al. Ocular pathogenesis and immune reaction after intravitreal dispase injection in mice
Wang et al. Th22 cells induce Müller cell activation via the Act1/TRAF6 pathway in diabetic retinopathy
Trinh et al. Th1-and Th2-related chemokine and chemokine receptor expression on the ocular surface in endotoxin-induced uveitis
JP5800263B2 (ja) アレルギー性鼻炎治療剤のスクリーニング方法およびその利用
Atef et al. Interleukin-36α Expression in Vitiligo Skin Lesions and Its Association with Disease Pattern, Activity, and Severity
Huo et al. Influence of plasma exchange on transplantation related immune function in patients with liver failure.
US9782385B2 (en) Artificial tears solution combination
US20250312412A1 (en) Methods for treating dry eye disease
Xing et al. Heme oxygenase-1-enriched tolerogenic dendritic cell-derived exosomes attenuate lupus nephritis by restoring immune balance and iron homeostasis

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20201202